The MDR-10X series of cellular immunotherapy products, including MDR-101 and MDR-102, are paradigms of personalized and precision medicine. These products are manufactured from living transplant kidney donor-derived stem cells. The cellular source materials are engineered into the final MDR-10X product using patent protected methods and processes. The composition of the final cellular immunotherapy product is a unique formulation of multiple different types of hematopoietic (i.e., blood or bone marrow derived) cells. The doses of CD34+ hematopoietic stem and progenitor cells (HSC) and the CD3+ T cells are critical to the action of the MDR-10X product. Cell doses are guided by the degree of immunologic disparity between the recipient and donor (i.e., degree of human leukocyte antigen (HLA)-match or HLA-mismatch). A single dose of MDR-10X can produce hematologic mixed chimerism. Hematologic mixed chimerism represents the co-existence of both recipient-derived and donor-derived blood and immune cells in the recipient. Mixed chimerism supports clonal deletion and immune regulation, the biologic mechanisms underlying immune tolerance. Essentially, MDR-10X can "reprogram" a kidney transplant recipient's immune system to specifically not react against and potentially destroy the transplant organ itself.